- Home
- ALPS vs CRBP Comparison
ALPS vs CRBP Comparison
Compare ALPS & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALPS | CRBP |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.4M | 170.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ALPS | CRBP |
|---|---|---|
| Price | $0.91 | $7.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $50.29 |
| AVG Volume (30 Days) | 56.5K | ★ 171.3K |
| Earning Date | 07-24-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,741,201.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $220.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 26.69 | N/A |
| 52 Week Low | $0.56 | $4.64 |
| 52 Week High | $15.00 | $20.56 |
Technical Indicators
Market Signals| Indicator | ALPS | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 45.37 | 33.54 |
| Support Level | $0.89 | $7.33 |
| Resistance Level | $1.02 | $9.57 |
| Average True Range (ATR) | 0.07 | 0.51 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 49.73 | 3.58 |
Price Performance
Historical ComparisonAbout ALPS ALPS Group Inc Ordinary Share
ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.